Greek looper

Systematic position. The Greek looper (Biston graecarius) belongs to the order Lepidoptera and the family Geometridae. This species is recognized for its specific development patterns associated with temperate and southern climates, making it a notable pest in orchards and woodland areas where its host plants are present.

Host plants. Biston graecarius is known to infest a variety of woody plants, particularly those belonging to the Rosaceae family. Primary economic crops at risk include apples, pears, cherries, and plums. The pest can transition from wild shrubs and neglected trees to commercial orchards, causing significant stress to cultivated plants due to defoliation.

Biology and life cycle. The life cycle involves four distinct stages: egg, larva (caterpillar), pupa, and adult moth. The insect typically overwinters in the pupal stage, buried in the soil near the base of host trees. Adult emergence coincides with early spring temperatures. Following mating, females lay eggs in clusters on branches or within bark crevices, which hatch into larvae that feed ravenously on expanding buds and foliage.

Damage and economic significance. The larval stage is responsible for the destructive feeding behavior. Young caterpillars begin by skeletonizing leaves, while older larvae consume the entire leaf lamina, leaving only veins. Heavy infestations lead to severe defoliation, which causes significant physiological damage to trees, reduced vigor, stunted growth, and a marked decline in the yield potential of the affected orchard.

Control measures. Integrated Pest Management (IPM) strategies are essential for controlling the Greek looper population.

• Application of sticky bands around tree trunks to prevent caterpillars from climbing.
• Mechanical cultivation of soil under the tree canopy to destroy over-wintering pupae.
• Timely monitoring of moth flights using light or pheromone traps.
• Strategic use of biological or chemical insecticides during the early larval development stages when caterpillars are most vulnerable to treatments.